Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, June 28 '25)

Image
By G.M.

 


    Antiviral Res

  1. HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al
    Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.
    Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217.
    PubMed         Abstract available


    Clin Infect Dis

  2. HARUN MGD, Sumon SA, Anwar MMU, Mohona TM, et al
    Infection Prevention and Control Knowledge, Attitudes, and Practices of Healthcare Workers in Tertiary Care Hospitals in Bangladesh During Coronavirus Disease 2019: A Multicenter Cross-sectional Survey.
    Clin Infect Dis. 2025 Jun 25:ciaf246. doi: 10.1093.
    PubMed         Abstract available

  3. DUONG KS, Henry SS, Duong TQ
    SARS-CoV-2 infection increases long-term risk of pneumonia in an urban population: an observational cohort study up to 46 months post-infection.
    Clin Infect Dis. 2025 Jun 25:ciaf345. doi: 10.1093.
    PubMed         Abstract available

  4. OPENSHAW JJ, Chen J, Rodriguez R, Gottlieb M, et al
    The Effect of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE).
    Clin Infect Dis. 2025 Jun 18:ciaf225. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  5. TARBUCK NN, Garushyants SK, McBride DS, Dennis PM, et al
    Persistence of SARS-CoV-2 Alpha Variant in White-Tailed Deer, Ohio, USA.
    Emerg Infect Dis. 2025;31:1319-1329.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  6. WHITELEY TD, Stimson J, Brown CS, Robotham JV, et al
    Modeling the impact of health care worker masking to reduce nosocomial SARS-CoV-2 transmission under varying adherence, prevalence, and transmission settings.
    Infect Control Hosp Epidemiol. 2025 Jun 27:1-7. doi: 10.1017/ice.2025.
    PubMed         Abstract available


    Int J Infect Dis

  7. CHAPMAN A, Barouch DH, Lip GYH, Pliakas T, et al
    Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: a systematic review and meta-analysis.
    Int J Infect Dis. 2025 Jun 24:107958. doi: 10.1016/j.ijid.2025.107958.
    PubMed         Abstract available

  8. PAUL E, Brown GW, Dechamps M, Kalk A, et al
    Corrigendum to "COVID-19: an 'extraterrestrial' disease?", [International Journal of Infectious Diseases, Volume 110, 155-159, September 2021].
    Int J Infect Dis. 2025;158:107951.
    PubMed        

  9. TEODORO LI, Ovsyannikova IG, Grill DE, Poland GA, et al
    Seroprevalence of RSV Antibodies in a Contemporary (2022 - 2023) Cohort of Adults.
    Int J Infect Dis. 2025 Jun 21:107964. doi: 10.1016/j.ijid.2025.107964.
    PubMed         Abstract available

  10. JOSEPH JT, Grau-Sepulveda M, Griffith BC, Lufes N, et al
    Evaluating the introduction of COVID-19 oral antivirals through a test and treat program: outcomes from a cohort study in four African countries.
    Int J Infect Dis. 2025 Jun 19:107956. doi: 10.1016/j.ijid.2025.107956.
    PubMed         Abstract available

  11. TSUCHIHASHI Y, Tamura K, Matsumoto K, Mitsushima S, et al
    Comparative analysis of streptococcal toxic shock syndrome caused by three beta-hemolytic streptococcal species in Japan.
    Int J Infect Dis. 2025 Jun 18:107962. doi: 10.1016/j.ijid.2025.107962.
    PubMed         Abstract available

  12. ESTILL J, Belayneh EG, Beale S, Keiser O, et al
    Estimation of the number of people affected by post COVID-19 condition in Switzerland in 2023: A mathematical model.
    Int J Infect Dis. 2025 Jun 18:107963. doi: 10.1016/j.ijid.2025.107963.
    PubMed         Abstract available


    J Med Virol

  13. SANCHEZ-SIMARRO A, Carretero D, Grau B, Martinez-Perez M, et al
    Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals.
    J Med Virol. 2025;97:e70463.
    PubMed         Abstract available

  14. WANG Y, Sun H, Liu Y, Song Y, et al
    TMEM106B Supports Viral Entry and Syncytia Formation Mediated by the Spike Proteins From Omicron BA.2.86 and JN.1.
    J Med Virol. 2025;97:e70439.
    PubMed         Abstract available

  15. BARY F, Karunananda MV, Jeewandara C, Danasekara S, et al
    Changes in Population Immunity to Omicron SARS-CoV-2 Variants and Selected Sarbecoviruses From 2020 to 2023 in Urban Colombo, Sri Lanka.
    J Med Virol. 2025;97:e70462.
    PubMed         Abstract available


    JAMA

  16. GRUNEBAUM A, Chervenak FA
    Professional Responsibility for COVID-19 Vaccination in Pregnancy.
    JAMA. 2025 Jun 25. doi: 10.1001/jama.2025.11328.
    PubMed        


    Lancet


  17. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    PubMed         Abstract available

  18. PAIL O, Lin MJ, Anagnostou T, Brown BD, et al
    Cancer vaccines and the future of immunotherapy.
    Lancet. 2025 Jun 17:S0140-6736(25)00553-7. doi: 10.1016/S0140-6736(25)00553.
    PubMed         Abstract available


    Lancet Infect Dis

  19. LIU JW, Lai CC, Hsueh PR
    Resurgence of human metapneumovirus in the post-COVID-19 era: pathogenesis, epidemiological shifts, clinical impact, and future challenges.
    Lancet Infect Dis. 2025 Jun 20:S1473-3099(25)00240.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  20. DIAZ MH, Hersh AL, Olson J, Shah SS, et al
    Mycoplasma pneumoniae Infections in Hospitalized Children - United States, 2018-2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:394-400.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »